Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
about
Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastomaNeuroblastomaStem cell transplantation for neuroblastomaNeuroblastoma: issues in transplantationOverview and recent advances in the treatment of neuroblastoma.Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysisOxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastomaPhase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory NeuroblastomaImpact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 studyCriteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.Genetically InFormed therapies--a "GIFT" for children with cancerAdult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature.Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomasRelevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma.Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.Promising therapeutic targets in neuroblastomaDifferent outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group.Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma.Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumoursLack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastomaKIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With NeuroblastomaTargeted radionuclide therapy.Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
P2860
Q24201280-05BE919B-59FB-4888-A12A-752F16062604Q24617733-46DD6607-B69B-49A7-AE67-BA4F0ADCEA18Q24629221-309F8ED3-EF3E-460A-8E75-07317B73671CQ27008197-E6ACBE30-0B38-46E0-B145-F4BFD915D896Q30238693-32813792-F9F6-43F4-A542-93F417947826Q33394925-D3981DEC-FF61-4880-AA2E-D1E8FFD9A8C3Q33409568-9454419A-8BEA-4AE4-84EE-57B7F7C79907Q33419558-08628FE4-8DD0-4B0E-9303-198EC407013AQ33419875-0FD95830-0AEC-4CA0-AA54-784D94327B00Q33420546-3FE0020A-FD73-4F44-95F5-34D052FBE4C3Q33427090-0D6B3DA6-5731-4EA2-A4FA-4C6C8DE5637CQ33429535-F6EFCC4B-C2E7-4519-97CC-1EF17434B7C8Q33691441-1898651C-7B31-4505-8556-4B47ADAA170DQ33834340-80ECE830-465B-4708-B311-02052FCFAF21Q33887843-8EAE0891-7FA5-45AD-A8F6-F8BB1ACACDFFQ33964937-2AAF898E-B028-4EB8-845B-B446B511496AQ34117552-96B8FAAC-CF10-454C-B1CD-69B53D6E8867Q34270304-8CA420A8-A6B8-4964-AB3B-171C189E6C8AQ34310934-950BAC6E-AEA5-4C24-A570-AC553A320B1CQ34424834-2C129386-9D30-4CDD-8366-42DF07EFF6F0Q34576380-FBC6CC3D-CDD4-4CCB-8197-43BFC758877BQ34589401-E77E6495-EC75-44EE-98A3-22DB6E998328Q35074813-168FE2F5-8F54-4791-A0DD-7539DDF133A5Q35077703-76891361-28D5-4636-915D-2899E81CB0EFQ35109012-9D2D5789-C546-46B7-A28A-4AC7B9652F4EQ35627829-6A7FF754-3F67-43AF-BDCB-3664AEAC4488Q35637861-6E468F08-D812-40E4-AD8A-102A8681738DQ36013113-BE525AB6-A693-4F1E-BDD5-B2AB41781E5AQ36055313-4EDC3389-1813-4410-A164-2A8D679D9238Q36167173-DE0480E7-F398-478C-98AC-CCF49902B42AQ36294179-9295A5B6-100E-4670-8844-E5CEF5CAF476Q36353230-A32AFCC3-E078-45B1-9CB3-766AAB8875EAQ36411942-29396CC5-C2A1-4571-9B80-7BCDE6BCBEC4Q36510103-8774703B-C6A2-4294-B0F6-2D7D7F4C068BQ36782374-F4436F91-4E24-46A1-A2D6-4BC2D15A6C92Q37078231-FBE9DC90-D5E2-4E62-922E-E3B3D2B334F2Q37130228-322B953F-78AB-425E-AD0B-347C3773C1E6Q37148148-3B815F3F-A0CC-4790-8313-8A2D7CAD13C6Q37334748-6DCC85D1-FCC4-4213-9830-59545E148269Q37411657-BF5621B1-93D4-4B75-8CB0-8ACFD02B1A92
P2860
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Phase II study on the effect o ...... y in refractory neuroblastoma.
@en
Phase II study on the effect o ...... y in refractory neuroblastoma.
@nl
type
label
Phase II study on the effect o ...... y in refractory neuroblastoma.
@en
Phase II study on the effect o ...... y in refractory neuroblastoma.
@nl
altLabel
Phase II study on the effect o ...... py in refractory neuroblastoma
@en
prefLabel
Phase II study on the effect o ...... y in refractory neuroblastoma.
@en
Phase II study on the effect o ...... y in refractory neuroblastoma.
@nl
P2093
P356
P1476
Phase II study on the effect o ...... y in refractory neuroblastoma.
@en
P2093
Alekist Quach
Gregory Yanik
Janet Veatch
John Huberty
John M Maris
Julia Messina
Katherine K Matthay
Leslie S Kersun
Patricia Brophy
Randall A Hawkins
P304
P356
10.1200/JCO.2006.09.3484
P407
P577
2007-03-01T00:00:00Z